A novel treatment of cystic fibrosis acting on-target: cysteamine plus epigallocatechin gallate for the autophagy-dependent rescue of class II-mutated CFTR

We previously reported that the combination of two safe proteostasis regulators, cysteamine and epigallocatechin gallate (EGCG), can be used to improve deficient expression of the cystic fibrosis transmembrane conductance regulator (CFTR) in patients homozygous for the CFTR Phe508del mutation. Here...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cell Death Differ
Hauptverfasser: Tosco, A, De Gregorio, F, Esposito, S, De Stefano, D, Sana, I, Ferrari, E, Sepe, A, Salvadori, L, Buonpensiero, P, Di Pasqua, A, Grassia, R, Leone, C A, Guido, S, De Rosa, G, Lusa, S, Bona, G, Stoll, G, Maiuri, M C, Mehta, A, Kroemer, G, Maiuri, L, Raia, V
Format: Artigo
Sprache:Inglês
Veröffentlicht: Nature Publishing Group 2016
Schlagworte:
Original Paper
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4947669/
https://ncbi.nlm.nih.gov/pubmed/27035618
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/cdd.2016.22
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge